Ye C. Guo

Tianjin, 301600, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

Clinical Phenotype, Molecular Architecture, and Survival Follow-Up in NRAS- and KRAS-Mutated Juvenile Myelomonocytic Leukemia.

Clinical Phenotype, Molecular Architecture, and Survival Follow-Up in NRAS- and KRAS-Mutated Juvenile Myelomonocytic Leukemia.

Journal: Cancers

Published: May 29, 2026

Pharmacokinetics, Efficacy, and Safety Profiles of Mitoxantrone Hydrochloride Liposome Plus Cytarabine in Pediatric Patients With Newly Diagnosed Acute Myeloid Leukemia.

Pharmacokinetics, Efficacy, and Safety Profiles of Mitoxantrone Hydrochloride Liposome Plus Cytarabine in Pediatric Patients With Newly Diagnosed Acute Myeloid Leukemia.

Journal: Pediatric blood & cancer

Published: January 16, 2026

Successful allogeneic hematopoietic stem cell transplantation in children with myeloid malignancies secondary to GATA2 deficiency using decitabine-containing busulfan conditioning.

Successful allogeneic hematopoietic stem cell transplantation in children with myeloid malignancies secondary to GATA2 deficiency using decitabine-containing busulfan conditioning.

Journal: Bone marrow transplantation

Published: December 28, 2025

Genomic Landscape and Clinical Outcomes of Advanced Pediatric Myelodysplastic Syndromes.

Genomic Landscape and Clinical Outcomes of Advanced Pediatric Myelodysplastic Syndromes.

Journal: European journal of haematology

Published: December 16, 2025

Early BCR::ABL1 Reduction as a Predictor of Deep Molecular Response in Pediatric Chronic-Phase Chronic Myeloid Leukemia.

Early BCR::ABL1 Reduction as a Predictor of Deep Molecular Response in Pediatric Chronic-Phase Chronic Myeloid Leukemia.

Journal: Cancers

Published: November 11, 2025

Nomogram-based prediction models for clinical outcomes in pediatric RUNX1::RUNX1T1-positive acute myeloid leukemia: a retrospective analysis from AML-CAMS serial trials.

Nomogram-based prediction models for clinical outcomes in pediatric RUNX1::RUNX1T1-positive acute myeloid leukemia: a retrospective analysis from AML-CAMS serial trials.

Journal: Frontiers in oncology

Published: November 11, 2025

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

Journal: The oncologist

Published: October 31, 2025

Avatrombopag for platelet engraftment after allogeneic hematopoietic stem cell transplantation in children: a retrospective clinical study

Avatrombopag for platelet engraftment after allogeneic hematopoietic stem cell transplantation in children: a retrospective clinical study

Journal: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics

Published: October 22, 2025

Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials.

Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials.

Journal: Leukemia & lymphoma

Published: August 19, 2025

Immunoglobulin NGS enhance residual disease detection and prognosis in pediatric Ph+ acute lymphoblastic leukemia.

Immunoglobulin NGS enhance residual disease detection and prognosis in pediatric Ph+ acute lymphoblastic leukemia.

Journal: Frontiers in immunology

Published: July 31, 2025

A Significant Risk Factor for Post-Transplant Lymphoproliferative Disorder in Pediatric Recipients: Low CD3+CD4+ T Cell Count at 30 Days after Hematopoietic Stem Cell Transplantation.

A Significant Risk Factor for Post-Transplant Lymphoproliferative Disorder in Pediatric Recipients: Low CD3+CD4+ T Cell Count at 30 Days after Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: July 15, 2025

Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance.

Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance.

Journal: Annals of hematology

Published: June 29, 2025

Showing 1-12 of 127

Last Updated: 09/26/2026